New Market Study: "Exelon (Alzheimer's disease) - Analysis and Forecasts to 2022"
GlobalData's pharmaceuticals report, "Exelon (Alzheimer's disease) - Analysis and Forecasts to 2022" provides Exelon global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press...
View full press release